Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity
about
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersGenetically engineered mouse models of Parkinson's diseaseNeurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson's diseaseAge-dependent effects of A53T alpha-synuclein on behavior and dopaminergic functionCircadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse modelVesicular integrity in Parkinson's diseaseMice genetically depleted of brain serotonin display social impairments, communication deficits and repetitive behaviors: possible relevance to autismDopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's diseaseSpontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein ExpressionThe Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat.Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.Behavioral phenotyping of mouse models of Parkinson's disease.Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's diseaseDeterminants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions.Neuroscience and heart-brain medicine: the year in review.Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegenerationInducible dopaminergic glutathione depletion in an α-synuclein transgenic mouse model results in age-related olfactory dysfunction.Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease.A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Vivo-morpholinos induced transient knockdown of physical activity related proteins.Intact olfaction in a mouse model of multiple system atrophy.Non-motor and motor features in LRRK2 transgenic mice.Noradrenaline and Parkinson's disease.Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models.Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonismIntra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.Monoamine reuptake inhibitors in Parkinson's disease.Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine ToxicityIndustrial toxicants and Parkinson's disease.Monoamine transporters: vulnerable and vital doorkeepers.Sleep disturbances in Alzheimer's and Parkinson's diseases.Comparative Proteomic Analysis of Carbonylated Proteins from the Striatum and Cortex of Pesticide-Treated Mice.α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficitsRetinal dopamine mediates multiple dimensions of light-adapted vision.
P2860
Q26826093-633D134E-C3F6-48CF-9293-4AE74AA19C92Q26852964-679198F0-8F9F-4F72-94C2-05B17D9E2E66Q27012533-78BA1A87-A26C-4F4E-B0F7-C4FB3F25DF25Q27330366-563D7E3F-D11B-4FF0-AF65-80C3E5280244Q28384426-4FDFEDBC-BA5C-4B51-9F09-B0853F25C5A9Q28385737-88A6BF78-ADB0-4FE6-ADAD-F1283308C611Q28390641-0BD9B627-B0D9-42C5-93C7-08CDCE51E1CDQ28511558-149107AD-48EC-43A0-B95A-E16BF0C19CAFQ30359033-C1F6EF82-C407-4177-8E6A-5627D1BF2A45Q30430534-56D57167-0A2C-4816-9C3C-0251440CF86DQ30487373-07349ADD-EE34-4B68-90AD-B636114AD16DQ33671819-67C8A1A0-A080-4650-B3D3-2CEC4344269EQ33724885-307CD05D-7D35-43A8-B921-2E3509D8532FQ33778472-7171D0C3-41AA-46A9-BCC3-99C105028B5BQ33820609-1C626D4E-DA42-4390-B025-64F729D77BDDQ33882719-9685648C-4813-4FF1-A5D9-5FBEAE7ED594Q33896138-B4EE327C-0839-4B26-A8EA-C29A753A71EAQ34094065-40DF52E6-D569-42F1-B47E-F7F2B713B306Q34182826-87A4CB3F-FF97-4BBB-83DA-6BB2BB26343FQ34307633-08A7502B-8F63-4FDF-B9C8-D3027635E345Q34384338-E034673C-E093-4902-A272-8348E8706AFAQ34441722-DCA07252-989E-4147-8C80-2314C46E7638Q34482196-87434B05-7CF6-41C4-A550-A4BC16F95AE2Q34560077-BE47AD5A-5E81-4E36-A120-173959AAEC76Q34595165-9DC7B38C-CADD-4FA5-91CF-1FB987B76F70Q34695522-60B65ACD-3C53-4414-8F9A-863F5FA15BC3Q34732028-AA15BA86-DEDA-4FD8-93CC-6B19AAFD4796Q34922393-1486C2A7-C78D-4657-ADAD-C6A9A4458146Q35013240-870BBB49-3F11-481C-8514-E2E147DEC5DCQ35035322-F86E3A67-BD0A-45E4-913D-E26E25606C92Q35089378-7509FDED-BCDD-4821-AB8E-949380FDFF0CQ35142854-D5B0DCD6-4B36-4006-865A-8DDED510DDCCQ35165280-0DCE9B23-9387-4982-9656-77A9761CADEBQ35810975-EED9778C-AF41-4B89-A44F-80CE4FC5DA33Q35822952-28045045-C750-4E8A-81B3-7F1D690A1691Q35877150-E14CF524-9847-40AE-BE02-9B46FE3953C8Q35981780-263E77F2-524C-4622-84EB-7F155F6715DBQ35988085-25DD68C4-B661-4615-B60A-00359B2B4956Q36034871-A930133F-5F11-4369-BF25-DBB6B6205916Q36104677-FA7598B0-C678-42D0-924B-1279882A1BA7
P2860
Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity
@ast
Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity
@en
type
label
Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity
@ast
Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity
@en
prefLabel
Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity
@ast
Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity
@en
P2093
P2860
P1476
Nonmotor symptoms of Parkinson ...... ced monoamine storage capacity
@en
P2093
AliReza Noorian
Chad R Jackson
David Weinshenker
Gary W Miller
James G Greene
Kennie R Shepherd
P Michael Iuvone
Tonya N Taylor
W Michael Caudle
P2860
P304
P356
10.1523/JNEUROSCI.1495-09.2009
P407
P577
2009-06-01T00:00:00Z